Efficacy of succimer chelation for reducing brain Pb levels in a rodent model

Environmental Research

Volumn 78, Issue 2, 1998, Pages 168-176

  Smith, Donald ^a   Bayer, Lorna ^b   Strupp, Barbara J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Department of Obstetrics Gynecology   (United States)

Author keywords

Brain; Chelation; Lead; Neurotoxicity; Succimer

Indexed keywords

SUCCIMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHELATION; COGNITION; CONTROLLED STUDY; DRUG BRAIN LEVEL; ENVIRONMENTAL EXPOSURE; LEAD BLOOD LEVEL; MASS SPECTROMETRY; NEUROTOXICITY; NONHUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; RAT;

ANIMALIA; PRIMATES; RODENTIA;

EID: 0032145413     PISSN: 00139351     EISSN: None     Source Type: Journal    
DOI: 10.1006/enrs.1998.3854     Document Type: Article

References (39)

1. Alber S. A., Strupp B. J. An in-depth analysis of Pb effects in a delayed spatial alternation task: Assessment of mnemonic effects, side bias and proactive interference. Neurotox. Teratol. 18:1996;3-15.
2. Aposhian H. V., Aposhian M. M. Meso-2,3-dimercaptosuccinic acid: Chemical, pharmacological and toxicological properties of an orally effective metal chelating agent. Annu. Rev. Pharmacol. Toxicol. 30:1990;279-306.
3. Cantilena L. R., Klaassen C. D. The effect of chelating agents on the excretion of endogenous metals. Toxicol. Appl. Pharmacol. 63:1982;344-350.
4. Chisolm J. J. BAL, EDTA, DMSA and DMPS in the treatment of lead poisoning in children. Clin. Toxicol. 30:1992;493-504.
5. Cory-Slechta D. Mobilization of lead over the course of DMSA chelation therapy and long-term efficacy. J. Pharmacol. Exp. Ther. 246:1988;84-91.
6. Flegal A. R., Smith D. R. Current needs for increased accuracy and precision in measurements of low levels of lead in blood. Environ. Res. 58:1992;125-133.
7. Flegal A. R., Smith D. R. Measurements of environmental lead contamination and human exposure. Rev. Environ. Contam. Toxicol. 143:1995;1-45.
8. Fournier L., Thoas R., Garnier A., Houze P., Pradier F., Dally S. 2,3-dimercaptosuccinic acid treatment of heavy metal poisoning in humans. Med. Toxicol. 3:1988;499-504.
9. Friedheim E., Graziano J. H., Popovac D., Dragovic D., Kaul B. Treatment of lead poisoning by 2,3-dimercaptosuccinic acid. Lancet. 2:1978;1234-1236.
10. Frumkin H., Gerr F. Dimercaptousuccinic acid in the treatment of depression following lead exposure. Am. J. Indust. Med. 24:1993;701-706.
11. Glotzer D. E. The current role of 2,3-Dimercaptosuccinic acid (DMSA) in the management of childhood lead poisoning. Drug Saf. 9:1993;85-92.
12. Goldstein G., Asbury A., Diamond I. Pathogenesis of lead encephalopathy. Arch. Neurol. 31:1974;382-389.
13. Goyer R. A., Cherian M. G., Jones M. M., Reigart J. R. Role of chelating agents for prevention, intervention, and treatment of exposure to toxic metals. Environ. Health Perspect. 103:1995;1048-1052.
14. Graziano J. H. Role of 2,3-dimercaptosuccinic acid in the treatment of heavy metal poisoning. Med. Toxicol. 1:1986;155-162.
15. Graziano J. H., Leong J. K., Friedheim E. 2,3-dimercaptosuccinic acid: A new agent for the treatment of lead poisoning. J. Pharmacol. Exp. Ther. 206:1978;696-700.
16. Hilson J., Strupp B. J. Analyses of response patterns clarify lead effects in olfactory reversal and extra-dimensional shift tasks: Assessment of inhibitory control, associative ability, and memory. Behav. Neurol. 111:1997;532-542.
17. Jones M., Basinger M., Gale G., Atkins L., Smith A., Stone A. Effect of chelate treatments on kidney, bone, and brain lead levels of lead-intoxicated mice. Toxicology. 89:1994;91-100.
18. Lamsan J., Woolard D., Smith D. R. Changes in brain Pb with EDTA chelation determined with a stable lead isotope tracer and ICP-MS. Fund. Appl. Toxicol. 36:1997;37.
19. Liebelt E. L., Shannon M., Graef J. W. Efficacy of oral meso-2,3-dimercaptosuccinic acid therapy for low-level childhood plumbism. J. Pediatr. 124:1994;313-317.
20. Maiorino R. M., Akins J. M., Blaha K., Carter D. E., Aposhian H. V. Determination and metabolism of dithiol chelating agents. X. In humans, meso-2,3-dimercaptosuccinic acid is bound to plasma proteins via mixed disulfide formation. J. Pharmacol. Exper. Ther. 254:1990;570-577.
21. 2. Pediatrics. 92:1993;265-271.
22. McGown E. L., Tillotson J. A., Knudsen J. J., Dumlao C. R. Biological behavior and metabolic fate of the BAL analogues DMSA and DMPS. Proc. West. Pharmacol. Soc. 27:1984;169-176.
23. Lead in the Human Environment. 1980;National Acad. Press, Washington.
24. Measuring Lead Exposure in Infants, Children, and Other Sensitive Populations. 1993;National Acad. Press, Washington.
25. O'Flaherty E. J. Physiologically-based models for bone-seeking elements. II. Kinetics of lead disposition in rats. Toxicol. Appl. Pharmacol. 111:1991;313-333.
26. O'Flaherty E. J. Physiologically-based models for bone-seeking elements. IV. Kinetics of lead disposition in humans. Toxicol. Appl. Pharmacol. 118:1993;16-29.
27. O'Flaherty E. J. Physiologically-based models for bone-seeking elements. V. Lead absorption and disposition in childhood. Toxicol. Appl. Pharmacol. 131:1995;297-308.
28. Pappas J., Ahlquist J., Allen E., Banner W. Oral dimercaptosuccinic acid and ongoing exposure to lead: Effects on heme synthesis and lead distribution in a rat model. Toxicol. Appl. Pharmacol. 133:1995;121-129.
29. Patterson C. C. Contaminated and natural lead environments of Man. Arch. Environ. Health. 11:1965;344-360.
30. Patterson C. C. Delineation of separate brain regions used for scientific versus engineering modes of thinking. Geochem. Cosmochim. Acta. 58:1994;3321-3327.
31. Rice D. C. Behavioral effects of lead: Commonalities between experimental and epidemiologic data. Environ. Health Perspect. 104:1996;337-351.
32. Ruff H. A., Bijur P. E., Markowitz M., Ma Y. C., Rosen J. F. Declining blood lead levels and cognitive changes in moderately lead-poisoned children. J. Am. Med. Assoc. 269:1993;1641-1646.
33. Seaton C., Osterloh J., Smith D. R. Mobilization of skeletal Pb with ovarian hormone deficiency in a rodent model of menopausal osteopenia. Toxicol. Sci. (Suppl.). 42:1998;27.
34. Smith D. R., Flegal A. R. Stable isotopic tracers of lead mobilized by DMSA chelation in low lead-exposed rats. Toxicol. Appl. Pharmacol. 116:1992;85-91.
35. Smith D. R., Flegal A. R. Lead in the Biosphere: Recent trends. AMBIO. 24:1995;21-23.
36. 204. Environ. Res. 67:1994;39-57.
37. Smith D. R., Osterloh J., Niemeyer S., Flegal A. R. Stable isotope labeling of lead compartments in rats with ultra-low lead concentrations. Environ. Res. 57:1992;190-207.
38. Woolard D., Franks R., Smith D. R. An inductively coupled plasma-magnetic sector mass spectrometry method for stable lead isotope tracer studies. J. Anal. At. Spect. 1998.
39. Xu Z. F., Jones M. M. Comparative mobilization of lead by chelating agents. Toxicology. 53:1988;277-288.